Azure Transit Connect Electric

FPT Software Recognized in Everest Group ACES Automotive Engineering Services PEAK Matrix® Assessment 2023

Retrieved on: 
Monday, October 9, 2023

Global IT services provider FPT Software announced today that it has been positioned as a Major Contender in Autonomous, Connected, Electric, and Shared (ACES) Automotive Engineering Services PEAK Matrix® Assessment 2023 .

Key Points: 
  • Global IT services provider FPT Software announced today that it has been positioned as a Major Contender in Autonomous, Connected, Electric, and Shared (ACES) Automotive Engineering Services PEAK Matrix® Assessment 2023 .
  • View the full release here: https://www.businesswire.com/news/home/20231008530642/en/
    FPT Software has been recognized in Everest Group Autonomous, Connected, Electric, and Shared (ACES) Automotive Engineering Services PEAK Matrix® Assessment 2023.
  • The study is based on RFI responses from service providers, interactions with their automotive engineering leadership, client reference checks, and ongoing analysis of the engineering services market.
  • "This designation from Everest Group solidifies FPT Software's place as a full-stack service provider across the automotive engineering space," said Kinh Nguyen, Managing Director of Global Automotive & Manufacturing Solutions Group, FPT Software.

TATA Elxsi's 'TETHER' paves the way for Tata Motors Connected Vehicle Platform to scale new heights.

Retrieved on: 
Wednesday, January 4, 2023

In early 2019, Tata Motors collaborated with TATA Elxsi to adopt and adapt the TETHER Connected Vehicle Platform (CVP) towards a common standard technology stack to deliver scalability, differentiated features, high performance and expandable to Industry 4.0 to transform their internal operations.

Key Points: 
  • In early 2019, Tata Motors collaborated with TATA Elxsi to adopt and adapt the TETHER Connected Vehicle Platform (CVP) towards a common standard technology stack to deliver scalability, differentiated features, high performance and expandable to Industry 4.0 to transform their internal operations.
  • In addition, they enable secure and selective access to the platform and relevant data with its wider partner ecosystem, including dealers, and suppliers, to enrich customer experience.
  • TETHER CVP was built as a modular platform, which can be scaled up to offer a wide range of solutions with third-party applications through APIs.
  • The Connected Vehicle Program will unify and synergize data through a common digital services platform, enabling completely new services, innovative business models, and enhanced customer experience."

Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 11, 2022

Total Q2 2022 revenue of $7.4 million, up 139% from prior year

Key Points: 
  • Total Q2 2022 revenue of $7.4 million, up 139% from prior year
    DEER PARK, Ill., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the second quarter ended June 30, 2022.
  • Carglumic Acid sales in the second quarter of 2022 grew 100% over the first quarter of 2022.
  • Product sales and royalty revenue were $2.4 million for the second quarter of 2022 compared with $0.6 for the second quarter of 2021.
  • Conference Call and Webcast Information:
    As previously announced, Eton Pharmaceuticals will host its second quarter 2022 conference call as follows:

AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF ZONISADE™ (zonisamide oral suspension)

Retrieved on: 
Monday, July 18, 2022

WOBURN, Mass., July 18, 2022 /PRNewswire/ -- Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative products to serve the specific needs of overlooked patients, today announced the U.S. Food and Drug Administration (FDA) approval of ZONISADE™ (zonisamide oral suspension),

Key Points: 
  • "ZONISADE is the first and only FDA-approved oral liquid formulation of zonisamide, and it offers healthcare providers an important new treatment option for their patients with epilepsy," said Richard Blackburn, CEO of Azurity Pharmaceuticals.
  • "We are excited about this approval as we continue to grow our portfolio of liquid medications that meet the individual needs of certain patients."
  • "ZONISADE addresses an important unmet need in patients who have difficulty swallowing or who are unable or unwilling to take tablets."
  • "The FDA approval and availability of ZONISADE is a welcomed advancement for patients and their families who may be seeking a liquid formulation alternative to treat epilepsy."

AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF EPRONTIA™ (topiramate) oral solution

Retrieved on: 
Monday, November 8, 2021

WOBURN, Mass., Nov. 8, 2021 /PRNewswire/ --Azurity Pharmaceuticals, Inc. a private specialty pharmaceutical company focused on developing innovative products to meet the unique needs of patients with underserved conditions, today announced the U.S. Food and Drug Administration (FDA) approval of EPRONTIA(topiramate) oral solution, 25 mg/mL.

Key Points: 
  • WOBURN, Mass., Nov. 8, 2021 /PRNewswire/ --Azurity Pharmaceuticals, Inc. a private specialty pharmaceutical company focused on developing innovative products to meet the unique needs of patients with underserved conditions, today announced the U.S. Food and Drug Administration (FDA) approval of EPRONTIA(topiramate) oral solution, 25 mg/mL.
  • "EPRONTIA's ready-to-use liquid formulation provides HCPs a therapy that addresses an unmet medical need."
  • Azurity Pharmaceuticals is a privately held, specialty pharmaceutical company that focuses on innovative products that meet the needs of patients with underserved conditions.
  • The company's patient-centric products span the cardiovascular, neurology, endocrinology, gastro-intestinal, institutional, and orphan markets, and have benefited millions of patients.

Ford to Discuss the All-New E-Transit All-Electric Van and Opportunities for Connected Commercial Vehicles

Retrieved on: 
Thursday, November 12, 2020

Ford Motor Company leaders will discuss the all-new, all-electric E-Transit with Wolfe Research on Tuesday, Nov. 17.

Key Points: 
  • Ford Motor Company leaders will discuss the all-new, all-electric E-Transit with Wolfe Research on Tuesday, Nov. 17.
  • With a 45% share in the U.S. of the commercial pickup and van commercial market, Ford is extending its leadership by introducing the zero-emissions, all-electric E-Transit a new era of the worlds best-selling cargo van brand.
  • Ford team will provide details about E-Transits customer benefits and future revenue opportunities from expanded dealer services, integrated charging solutions, connected data networks, mobile applications and subscriptions.
  • For more information regarding Ford, its products and Ford Motor Credit Company, please visit www.corporate.ford.com .